ALK and non-small cell lung carcinoma: Based on the findings of these 2 studies,[16,22] alectinib is deemed essential in treating NSCLC, particularly in preventing CNS metastasis in ALK-positive Japanese patients, with a minimal risk of alectinib refractory development.